Raymond James & Associates Has $5.63 Million Position in Stevanato Group S.p.A. (NYSE:STVN)

Raymond James & Associates boosted its holdings in Stevanato Group S.p.A. (NYSE:STVN) by 21.8% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 281,455 shares of the company’s stock after buying an additional 50,380 shares during the period. Raymond James & Associates’ holdings in Stevanato Group were worth $5,629,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of STVN. Tri Locum Partners LP acquired a new stake in shares of Stevanato Group during the second quarter worth $10,370,000. Thrivent Financial for Lutherans acquired a new position in shares of Stevanato Group in the 2nd quarter valued at approximately $30,477,000. Thornburg Investment Management Inc. raised its position in shares of Stevanato Group by 279.1% in the 2nd quarter. Thornburg Investment Management Inc. now owns 746,218 shares of the company’s stock valued at $13,690,000 after buying an additional 549,378 shares in the last quarter. Comgest Global Investors S.A.S. raised its position in shares of Stevanato Group by 56.8% in the 2nd quarter. Comgest Global Investors S.A.S. now owns 394,120 shares of the company’s stock valued at $7,228,000 after buying an additional 142,754 shares in the last quarter. Finally, Raymond James Trust N.A. grew its holdings in shares of Stevanato Group by 18.7% during the 2nd quarter. Raymond James Trust N.A. now owns 10,239 shares of the company’s stock valued at $188,000 after purchasing an additional 1,613 shares during the last quarter.

Stevanato Group Stock Performance

Shares of Stevanato Group stock opened at €19.59 ($21.29) on Friday. Stevanato Group S.p.A. has a 52-week low of €16.56 ($18.00) and a 52-week high of €34.73 ($37.75). The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.13 and a current ratio of 1.74. The company’s 50 day moving average price is €19.57 and its 200-day moving average price is €20.51.

Stevanato Group (NYSE:STVN) last released its earnings results on Tuesday, August 6th. The company reported €0.09 ($0.10) EPS for the quarter, missing analysts’ consensus estimates of €0.10 ($0.11) by (€0.01) (($0.01)). The firm had revenue of €259.60 million for the quarter, compared to analyst estimates of €254.92 million. Stevanato Group had a return on equity of 10.89% and a net margin of 11.27%. The company’s revenue for the quarter was up 1.7% compared to the same quarter last year. During the same period last year, the firm earned $0.15 EPS. On average, sell-side analysts forecast that Stevanato Group S.p.A. will post 0.5 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the stock. Citigroup reduced their target price on shares of Stevanato Group from $30.00 to $28.00 and set a “buy” rating on the stock in a report on Wednesday, August 7th. Morgan Stanley lowered their price objective on shares of Stevanato Group from $26.00 to $22.00 and set an “equal weight” rating on the stock in a report on Monday, July 15th.

Stevanato Group Company Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.